These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27398741)

  • 1. What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?
    Newall AT
    Hum Vaccin Immunother; 2016 Oct; 12(10):2666-2669. PubMed ID: 27398741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.
    Willem L; Blommaert A; Hanquet G; Thiry N; Bilcke J; Theeten H; Verhaegen J; Goossens H; Beutels P
    Hum Vaccin Immunother; 2018 May; 14(5):1218-1229. PubMed ID: 29420161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination.
    Chen C; Beutels P; Newall AT
    Vaccine; 2018 Apr; 36(16):2057-2060. PubMed ID: 29548606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the costs and benefits of pneumococcal vaccination in adults.
    Porchia BR; Bonanni P; Bechini A; Bonaccorsi G; Boccalini S
    Expert Rev Vaccines; 2017 Feb; 16(2):93-107. PubMed ID: 27680425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
    Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
    Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
    Jiang Y; Gauthier A; Keeping S; Carroll S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults.
    Atwood M; Beausoleil L; Breton MC; Laferriere C; Sato R; Weycker D
    Can J Public Health; 2018 Dec; 109(5-6):756-768. PubMed ID: 29981104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older.
    Nishikawa AM; Sartori AMC; Mainardi GM; Freitas AC; Itria A; Novaes HMD; de Soárez PC
    Vaccine; 2018 May; 36(19):2510-2522. PubMed ID: 29618414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
    Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
    Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium.
    Blommaert A; Bilcke J; Willem L; Verhaegen J; Goossens H; Beutels P
    Vaccine; 2016 Apr; 34(18):2106-12. PubMed ID: 26988257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.
    Falkenhorst G; Remschmidt C; Harder T; Hummers-Pradier E; Wichmann O; Bogdan C
    PLoS One; 2017; 12(1):e0169368. PubMed ID: 28061505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
    Sohn HS; Suh DC; Jang E; Kwon JW
    J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
    Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP
    PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions.
    Treskova M; Scholz SM; Kuhlmann A
    Pharmacoeconomics; 2019 Sep; 37(9):1093-1127. PubMed ID: 31025189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.